MRNA vs TXN
Head-to-Head Stock Analysis & Investment Rating
Last Updated: Jul 27, 2026
MRNA
TXN
Investment Advisor Scores
TXN
AI Analyst Insights
Detailed Metrics Comparison
| Metric | MRNA | TXN | Winner |
|---|---|---|---|
|
Valuation
Lower P/E and PEG ratios suggest a stock may be undervalued relative to earnings and growth. Value investors prefer lower multiples. |
|||
| Forward P/E | 23.0415 | 38.9105 | MRNA |
| PEG Ratio | 0 | 1.416 | Tie |
|
Growth
Higher revenue and earnings growth rates indicate a company is expanding faster. Strong growth often justifies premium valuations. |
|||
| Revenue Growth | 260.2% | 18.6% | MRNA |
| Earnings Growth | -85.1% | 31.3% | TXN |
|
Quality & Profitability
Higher Tradestie Score and profit margins reveal how efficiently a company operates. Strong profitability indicates competitive advantages. |
|||
| Tradestie Score | 52.0/100 | 47.5/100 | MRNA |
| Profit Margin | -143.6% | 29.1% | TXN |
|
Risk Profile
Lower Beta and Implied Volatility values indicate reduced market risk. Conservative investors favor stocks with less price volatility. |
|||
| Beta | 1.00 | 1.00 | Tie |
|
Sentiment
AI Recommendation reflects overall analyst and proprietary sentiment. Stronger recommendations signal higher conviction. |
|||
| AI Recommendation | HOLD | HOLD | Tie |
Relative Price Performance (Last 90 Days)
Current Technical Phase
MRNA
NeutralMixed signals - no dominant trend phase, RSI 50
TXN
NeutralMixed signals - no dominant trend phase, RSI 50
Fundamentals Snapshot
| Metric | MRNA | TXN |
|---|---|---|
| Market Cap | — | — |
| Forward P/E | -11.0 | 28.5 |
| Trailing P/E | — | 42.2 |
| Revenue (TTM) | — | — |
| Revenue Growth | 0.0% | 0.2% |
| Gross Margin | -0.7% | 0.6% |
| Operating Margin | -5.6% | 0.4% |
| EPS | -7.88 | 6.60 |
| Dividend Yield | — | 0.02% |